Collectively, these observations suggest that the reduced plasma soluble CLEC-2 levels observed in breast cancer may reflect a multifactorial process, potentially involving ligand-mediated sequestration, receptor downregulation, assay interference, and limited expression from alternative cellular sources. Here, CLEC1B is linked to breast carcinoma.